RESUMEN
The compound OVS-103 showed dose-dependent anti-inflammatory and anti-arthritic effects in different acute and chronic test models in rats and mice. It produced inhibition of the exudate volume and the migration of leucocytes in the carrageenan induced pleurisy test in rats. OVS-103 showed poor inhibitory effect on granuloma formation induced by cotton pellet and had no anti-pyretic and analgesic property. ALD50 in both rats and mice was more than 2000 mg/kg, p.o. and 1500 mg/kg, i.p.
Asunto(s)
Animales , Antiinflamatorios no Esteroideos/farmacología , Artritis/tratamiento farmacológico , Permeabilidad Capilar/efectos de los fármacos , Cromonas/farmacología , Modelos Animales de Enfermedad , Edema/tratamiento farmacológico , Femenino , Dosificación Letal Mediana , Ratones , Pleuresia/tratamiento farmacológico , Embarazo , Ratas , Útero/efectos de los fármacosRESUMEN
Oral treatment of compound IIIA exhibited dose related inhibitory action in acute tests of carrageenan, histamine and dextran-induced oedema in rats. Marked inhibitory action of the compound was found when it was administered intraperitoneally in animals. It displayed prominent anti-arthritic activity in chronic tests of adjuvant and formaldehyde-induced arthritis in rats. It prevented the arthritis associated rise in total leucocyte count and erythrocyte sedimentation rate. It also lowered the levels of exudate volume and migration of leucocytes in carrageenan induced pleurisy in rats. It did not exhibit any analgesic, antipyretic or ulcerogenic effect. No mortality was recorded up to 2 g/kg in mice on oral or intraperitoneal treatment over a period of 72 hr.